Etrolizumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameEtrolizumab
Drug Alias Nameetrolizumabum依曲利珠单抗依卓利珠单抗Monoclonal antibody beta7依曲利单抗 +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionIntegrin alpha-4/beta-7 antagonistsIntegrin alpha-E/beta-7 antagonists
TargetsIntegrin alpha-4/beta-7Integrin alpha-E/beta-7
Therapy Area/IndicationsCrohn DiseaseColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[43] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche Ltd
Inactive CompaniesGenentech Inc
Active IndicationsCrohn Disease
Inactive IndicationsColitis, Ulcerative

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG